Karyopharm Therapeutics (KPTI) to Release Earnings on Wednesday

Karyopharm Therapeutics (NASDAQ:KPTI - Get Free Report) is expected to be issuing its Q1 2025 quarterly earnings data before the market opens on Wednesday, May 14th. Analysts expect the company to announce earnings of ($4.21) per share and revenue of $35.12 million for the quarter. Karyopharm Therapeutics has set its FY 2025 guidance at EPS.

Karyopharm Therapeutics (NASDAQ:KPTI - Get Free Report) last released its quarterly earnings data on Wednesday, February 19th. The company reported ($3.60) earnings per share for the quarter, beating analysts' consensus estimates of ($3.90) by $0.30. The company had revenue of $30.54 million for the quarter, compared to analysts' expectations of $30.29 million. On average, analysts expect Karyopharm Therapeutics to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Karyopharm Therapeutics Stock Down 11.6 %

Shares of NASDAQ KPTI opened at $6.27 on Wednesday. The firm's fifty day moving average is $5.59 and its 200 day moving average is $9.11. Karyopharm Therapeutics has a 52 week low of $3.51 and a 52 week high of $18.00. The company has a market cap of $53.73 million, a price-to-earnings ratio of -6.15 and a beta of 0.33.

Analyst Ratings Changes

Several equities analysts have recently commented on the stock. HC Wainwright upped their price objective on shares of Karyopharm Therapeutics from $7.00 to $56.00 and gave the company a "buy" rating in a research note on Wednesday, February 26th. Robert W. Baird lowered their price target on Karyopharm Therapeutics from $75.00 to $54.00 and set an "outperform" rating for the company in a research report on Monday, March 3rd. Finally, Royal Bank of Canada reiterated an "outperform" rating and issued a $45.00 price objective on shares of Karyopharm Therapeutics in a report on Thursday, February 20th. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $57.50.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.